spacer
home > ebr > summer 2019 > leveraging novel therapeutics and diagnostic assays
PUBLICATIONS
European Biopharmaceutical Review

Leveraging Novel Therapeutics and Diagnostic Assays
Immunotherapy is far from a novel concept, and its history is intriguing. It all began in 1891 when Dr William B Coley attempted to creatively harness the patient’s immune system. William achieved durable complete remission in several types of malignancies to include sarcoma, lymphoma, and testicular carcinoma by injecting mixtures of live and attenuated bacteria into patients’ tumours. Needless to say, we have come a long way.

Read full article from PDF >>
Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.
spacer
Marisa Pearce is Scientific Affairs Liaison at Molecular MD, an ICON company, and has over 10 years of experience in oncology biomarker test development. She has been involved in the planning and design of molecular tests across the continuum from translational research to clinical deployment. These efforts include research use only assays for solid tumour profiling to the commercialisation of companion diagnostics for minimal residual disease monitoring. Marisa's diverse background enables her to serve as subject matter expert on the selection and use of a variety of technologies for biomarker assay development. At MolecularMD, an ICON plc company, biopharma clients have access to a fit-for-purpose, platform-agnostic approach leveraging technology platforms such as NGS, droplet digital PCR, and multiplexed IHC for the codevelopment of clinical trial assays and/or downstream diagnostics aligned with the therapeutic program objectives.
spacer
Marisa Pearce
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page
Send to a friend
Privacy statement